9:30 AM
Mar 08, 2019
 |  BC Week In Review  |  Company News  |  Deals

J&J gets option to AdoRx's adenosine receptor antagonists for lung cancer

AdoRx granted Johnson & Johnson an exclusive option to research, develop and commercialize...

Read the full 44 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >